Apparatus Biyze For The Treatment Of Chronic Lymphocytic Leukaemia And Marginal Zone Lymphoma Dec 07, 2025 Dec 07, 2025 Prior to the granting of marketing authorisation by the MHRA, Biyze® had been approved by the European Commission for a number of indications and is currently the only drug approved for the treatment of MZL in Great Britain.
